Codexis, Inc.

Codexis, Inc.

Codexis, Inc.

Overview
Date Founded

2002

Headquarters

200 Penobscot Drive, Redwood City, CA, 94063, USA

Type of Company

Public

Employees (Worldwide)

161

Industries

Chemicals
Other Business & Consulting Services
Waste Management & Recycling
Biotechnology

Company Description

Codexis, Inc. engages in the discovery, development, and sale of proteins. The company offers enzyme optimization services and developing biocatalyst products. The firm operates through the following segments: Performance Enzymes and Novel Biotherapeutics. Its technologies accelerate the development of manufacturing processes for active pharmaceutical ingredients fine chemicals, agrochemicals, food ingredients, detergents and biofuels. The company was founded in January 2002 and is headquartered in Redwood City, CA.

Contact Data
Trying to get in touch with decision makers at Codexis, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Director, President & Chief Executive Officer

Senior Vice President, Finance & Chief Financial Officer

Senior Vice President, Chief Financial Officer & Principal Accounting Officer

Chief Science Officer Emeritus & Industrial Advisor

Senior Vice President, Strategic Development & General Manager, BioTherapeutics

Senior Vice President & General Manager, Performance Enzymes

Senior Vice President, Pharmaceutical Development, Quality & Regulatory

Senior Vice President, Research

Senior Vice President, Development & Operations

Vice President-Bio Therapeutics Research & Development

Board of Directors

Former President, Manufacturing Division at Merck & Co., Inc.

Former Senator from North Dakota

Director at Vitria Technology, Inc.

Co-Founder at Acepodia

Executive Vice President & Chief Financial Officer at Five Prime Therapeutics, Inc.

Advisor at Accompany

President & Chief Executive Officer at Sierra Oncology, Inc.

Chief Technical Officer at Allogene Therapeutics, Inc.

Senior Vice President-Research at Escient Pharmaceuticals, Inc.

Paths to Codexis, Inc.
Potential Connections via
Relationship Science
You
Codexis, Inc.
Owners & Shareholders
Details Hidden

NCM utilizes a long-term fundamental value investing methodology with a primary focus on small to mid-sized US companies. They practice research intensive, fundamental security selection and base their investment decisions on internally generated research and research obtained from outside sources. The firm focuses on intrinsic value by identifying securities which are mispriced relative to the real economic value they represent and on the expected timing for the mispricing to be corrected by market forces.

Details Hidden

Casdin Capital seeks to realize superior long-term adjusted total returns by primarily investing in underappreciated companies with innovative business models in the life sciences and healthcare industry. Their portfolio is generally comprised of small to mid-sized issuers in the following life sciences and healthcare sub-sectors: life sciences instrumentation and information technology, medical testing, drug development and distribution, synthetic biology and agriculture, livestock management and energy production. In addition, the firm also has discretion to invest in certain foreign equity securities if they determine that investments in such securities could generate risk-adjusted returns for their clients. Casdin Capital employs a primary research-intensive approach to investing that is thematically driven and fundamentally based and uses a range of investment strategies, primarily investing in publicly-traded equity or equivalent securities, both long and short, as well as a broad array of other securities.

Details Hidden

Telemark Asset Management seeks to invest primarily in long and short equity positions, but may invest in other types of securities, including debt securities, options and futures. They combine top-down analysis, to assess the various market segments, with bottom-up company specific research. They are likely, at times, to have a high concentration, long or short, in one or more sectors of the market. Telemark's primary objective is long-term performance, which may result in short-term volatility. While their fund is expected to focus on longer-term investments, it may also use short-term investments to protect longer-term positions, or to take advantage of short-term investment opportunities.

Recent Transactions
Details Hidden

Codexis, Inc. issued . USD Common Stock

Details Hidden

Codexis, Inc. issued USD Common Stock

Details Hidden

Codexis, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Auditor

Advised onCodexis, Inc. issued . USD Common Stock

Underwriter

Advised onCodexis, Inc. issued . USD Common Stock

Escrow Agent

Advised onCodexis, Inc. issued USD Common Stock

Global Co-Chair, Emerging Company Practice

Advised onCodexis, Inc. issued USD Common Stock

Managing Director, Health Care Investment Banking Group

Advised onCodexis, Inc. issued USD Common Stock

Managing Director

Advised onCodexis, Inc. issued USD Common Stock

Advisors & Consultants
Publicist

Senior Vice President & Principal at Lippert/Heilshorn & Associates, Inc.

Publicist

Professional at That’S Nice LLC

Clients

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Key Stats and Financials As of 2019
Market Capitalization
$1.66B
Total Enterprise Value
$839M
Earnings Per Share
$-0.21
Revenue
$68.5M
Net Profit
$-11.9M
EBITDA
$-7.78M
EBITDAMargin
-11.37%
Total Debt
$26.1M
Total Equity
$106M
Enterprise Value / Sales
12.25x
TEVNet Income
-70.28x
Debt TEV
0.03x
Three Year Compounded Annual Growth Rate Of Revenue
11.92%
Five Year Compounded Annual Growth Rate Of Revenue
14.16%
Non-Profit Donations & Grants
$10K - $25K
2017
$10K - $25K
2015
$10K - $25K
2014
Investments
Details Hidden

Arzeda Corp. operates as a synthetic biology company. It works thru agriculture, functionalized sweeteners and ingredients, chemicals and materials, and pharmaceuticals and diagnostics. The company was founded by Eric Althoff, David Baker, Daniela Grabs-Röthlisberger, Michael A. Martino and Alexandre Zanghellini in 2008 and is headquartered in Seattle, WA.

Details Hidden

Molecular Assemblies, Inc. develops an enzymatic deoxyribonucleic acid (DNA) synthesis technology designed to power the next generation of DNA-based products. The firm's technology will enable the reading and writing of DNA for industries including industrial synthetic biology and precision medicine, as well as emerging applications of DNA for data information storage, nanomachines, and bio-based electronics. The company was founded by William Efcavitch and Curt Becker in 2013 and is headquartered in San Diego, CA.

Investors
Details Hidden

Pequot Capital Management's investment philosophy is based on deep fundamental research and unbiased thematic analysis to identify and capitalize on market inefficiencies across an industry sector or a company's lifecycle. The firm invests in public equities, private equity, venture capital, distressed securities and a variety of fixed-income securities.Pequot Capital Management tends to invest in the stocks of US small-cap companies in the consumer services, health technology and commercial services sectors. They maintain a very high turnover rate.

Details Hidden

Chevron Technology Ventures invests in companies located in the US. The firm targets companies operating in the fields of advanced materials, emerging/alternative energy, information technology and oil & gas. It provides financing for early- to mid-stage companies as well as limited partnership funds.

Details Hidden

CMEA Capital focuses on investments in the life sciences, high technology and energy & materials sectors. They invest in both early- and late-stage ventures.Within the life sciences, the firm invests in biotechnology companies that engage in drug discovery and development. They invest in all stages in medical device companies with evolutionary products that have shorter R&D pathways. They also invest at mid- and late stages in companies with revolutionary products that tend to have longer R&D pathways.Within the high technology sector, CMEA focuses on high performance electronics companies in the consumer electronics and semiconductors markets.Within the energy & materials sector, the firm focuses on future fuels, premium power, alternative generation technologies, energy intelligence and energy efficient products.

Suppliers

Union Agricole Holding AG is a multi-national private company headquartered in Germany. The firm functions as an investment holding company.

ACS Dobfar SpA Wholesale: Consumer Non-Durables/Sundries | Agrate Brianza, Italy

ACS Dobfar SpA develops specialty pharmaceutical ingredients. Its products include active pharmaceutical ingredients, finished dosage form, and packaging. The company was founded by Marco Falciani in 1973 and is headquartered in Agrate Brianza, Italy.

Competitors
DuPont de Nemours, Inc. Plastics & Synthetics - Wilmington, DE

DuPont de Nemours, Inc. operates as a holding company, which engages in the development of specialty materials, chemicals, and agricultural products. It operates through the following segments: Electronics & Imaging; Nutrition & Biosciences; Transportation & Industrial; Safety & Construction, and Non-Core. The Electronics & Imaging segment provides permanent and process chemistries for the fabrication of printed circuit boards to include laminates and substrates, electroless and electrolytic metallization solutions, as well as patterning solutions and materials and innovative metallization processes for metal finishing, decorative, and industrial applications. The Nutrition & Biosciences segment provides solutions for the global food and beverage, dietary supplements, pharma, home and personal care, energy and animal nutrition markets. The Transportation & Industrial segment engineering resins, adhesives, silicones, lubricants and parts to engineers and designers in the transportation, electronics, healthcare, industrial and consumer end-markets to enable systems solutions for demanding applications and environments. The Safety & Construction segment provides engineering products and integrated systems for a number of industries including, worker safety, water purification and separation, aerospace, energy, medical packaging and building materials. The Non-Core segment supplier of key materials for the manufacturing of photovoltaic cells and panels, including SOLAMET metallization pastes, TEDLAR backsheet materials, and FORTASUN silicone encapsulants and adhesives. The company was founded in 1897 and is headquartered in Wilmington, DE.

Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

GlaxoSmithKline Plc Pharmaceuticals - Brentford, Gbr

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Codexis, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Codexis, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Codexis, Inc..